Mineralys Therapeutics, Common Stock Current Liabilities
| MLYS Stock | 15.42 0.46 3.07% |
Fundamental analysis of Mineralys Therapeutics, allows traders to better anticipate movements in Mineralys Therapeutics,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
Mineralys | Build AI portfolio with Mineralys Stock |
Mineralys Therapeutics, Common Company Current Liabilities Analysis
Mineralys Therapeutics,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Mineralys Therapeutics, Common has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Mineralys Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in current liabilities category among its peers.
Mineralys Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 802.2 M | ||||
| Shares Outstanding | 64.88 M | ||||
| Shares Owned By Insiders | 1.46 % | ||||
| Shares Owned By Institutions | 80.67 % | ||||
| Number Of Shares Shorted | 6.09 M | ||||
| Price To Book | 5.23 X | ||||
| EBITDA | (177.77 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 3.84 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Short Ratio | 4.49 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 40.0 | ||||
| Number Of Employees | 51 | ||||
| Beta | -0.39 | ||||
| Market Capitalization | 1 B | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
| Net Asset | 205.9 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.